Press and media
Press releases
More regular updates and key information, updates and news can be found through our tweets
CellCentric presents early haem clinical data at ASH
CellCentric to present haem clinical data at ASH
CellCentric strengthens leadership team
Latest tweets from @CellCentric
FDA and International Myeloma Society mtg: Instead of prior lines of therapy, it’s useful to assess patients by drug class refractory state.
There is a growing population in multiple myeloma that can benefit from therapeutic options that can be delivered in an outpatient community setting.
We continue to advance our pioneering oral p300/CBP inhibitor in Phase II. Inobrodib gets to the heart of progressing multiple myeloma by impacting MYC and IRF4.
FDA and International Myeloma Society mtg: Instead of prior lines of therapy, it’s useful to assess patients by drug class refractory state.
There is a growing population in multiple myeloma that can benefit from therapeutic options that can be delivered in an outpatient community setting.
We continue to advance our pioneering oral p300/CBP inhibitor in Phase II. Inobrodib gets to the heart of progressing multiple myeloma by impacting MYC and IRF4.
FDA and International Myeloma Society mtg: Instead of prior lines of therapy, it’s useful to assess patients by drug class refractory state.
There is a growing population in multiple myeloma that can benefit from therapeutic options that can be delivered in an outpatient community setting.
We continue to advance our pioneering oral p300/CBP inhibitor in Phase II. Inobrodib gets to the heart of progressing multiple myeloma by impacting MYC and IRF4.